Journal of Pain and Symptom Management
Volume 43, Issue 3 , Pages 549-557, March 2012

Impact of Infections on the Survival of Hospitalized Advanced Cancer Patients

  • Vincent Thai, MBBS, CCFP(C), MRCP(UK), ABPHM(USA)

      Affiliations

    • University of Alberta Hospital, Edmonton, Alberta
    • Corresponding Author InformationAddress correspondence to: Vincent Thai, MD, Palliative Care Services, University of Alberta Hospital, Walter C. Mackenzie Health Sciences Centre, 8440-112 Street, Edmonton, Alberta T6G 2B7, Canada.
  • ,
  • Francis Lau, PhD

      Affiliations

    • University of Victoria, Victoria, British Columbia, Canada
  • ,
  • Gary Wolch, MD

      Affiliations

    • University of Alberta Hospital, Edmonton, Alberta
  • ,
  • Ju Yang, MSc

      Affiliations

    • University of Victoria, Victoria, British Columbia, Canada
  • ,
  • Hue Quan, MSc

      Affiliations

    • Grey Nuns Hospital, Edmonton, Alberta
  • ,
  • Konrad Fassbender, PhD

      Affiliations

    • University of Alberta, Edmonton, Alberta

Accepted 12 April 2011. published online 10 November 2011.

Abstract 

Context

Advanced cancer patients remain highly susceptible to infections, leading to significant morbidity and mortality. A lack of consensus on the management of infections in this population stems from the heterogeneity of the patient group, divergent goals of care, and unknown prognosis with antibiotic treatment.

Objectives

This prospective single cohort study examined the impact of infection and its treatment on the survival of hospitalized advanced cancer patients compared with a similar cohort without infection.

Methods

A total of 441 patients were referred to the palliative care (PC) consult service in a tertiary hospital over a 12-month period. The occurrence of sepsis, organ-related infection, and antibiotic use were recorded on initial PC consult. Survival was calculated from the point of PC consult to the date of death.

Results

Of these patients, 16.6% suffered a recent episode of sepsis (with or without an identifiable organ-related infection) and 23.4% had a recent episode of organ-related infection without clinically evident sepsis. Among the patients with sepsis, organ-related infection, or both, 89.7% received antibiotics (intravenous, oral, or both). Median survival of septic and nonseptic patients was 15 and 42 days, respectively. Septic patients who responded poorly to treatment (nonresponders) had a median survival of five days vs. 142 days in good responders. This equates with a hazard ratio of 9.74 for death in antibiotic nonresponders (P<0.05). Median survival for patients with an untreated organ-related infection (no sepsis) was 27 days compared with 48 days in a similar cohort receiving antibiotic therapy. Among patients on IV antibiotics, nonresponders had a median survival of six days vs. 108 days in responders. For patients on oral antibiotics, nonresponders had a median survival of six days vs. 70 days in responders.

Conclusion

These findings suggest that a recent episode of sepsis and/or organ-related infection significantly reduces overall patient survival. Favorable antibiotic response is associated with an increase in median survival. These findings suggest that antibiotic treatment may prolong survival, and a time-limited trial may be indicated contingent on goals of care.

Key Words: Sepsis, infections, response to antibiotics, prognosticate, median survival

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0885-3924(11)00373-3

doi:10.1016/j.jpainsymman.2011.04.010

Journal of Pain and Symptom Management
Volume 43, Issue 3 , Pages 549-557, March 2012